Internal medicine

Live attenuated influenza vaccine

Disease

Immunogenicity

Coronavirus disease 2019 (COVID-19)

Infectious disease (medical specialty)

Outbreak

Virology

Randomized controlled trial

Vaccination

Immunology

Concomitant

2019-20 coronavirus outbreak

Seasonal influenza

Influenza vaccine

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Medicine

Immune system

The Lancet

Concomitant vaccination with ChAdOx1 or BNT162b2 plus an age-appropriate influenza vaccine raises no safety concerns and preserves antibody responses to both vaccines. Concomitant vaccination with both COVID-19 and influenza vaccines over the next immunisation season should reduce the burden on health-care services for vaccine delivery, allowing for timely vaccine administration and protection from COVID-19 and influenza for those in need.

Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial